Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders.
Zhang
Ao
A
Bioorganic and Medicinal Chemistry Laboratory, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. aozhang@mail.shcnc.ac.cn
Neumeyer
John L
JL
Baldessarini
Ross J
RJ
D018491:Dopamine Agonists / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use; D018492:Dopamine Antagonists / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use; D065127:Dopamine D2 Receptor Antagonists; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy; D015394:Molecular Structure; D009422:Nervous System Diseases / Q000188:drug therapy; D017447:Receptors, Dopamine D1 / Q000819:agonists / Q000037:antagonists & inhibitors; D017448:Receptors, Dopamine D2 / Q000819:agonists
D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2